CS Diagnostics Corp.

What they do

The company states it collaborates with universities, research institutions, and healthcare professionals to develop, license, and commercialize diagnostic and therapeutic products, including its flagship product CS Protect-Hydrogel and exclusive U.S. distribution rights for MEDUSA-SDP. It also says it provides international medical-sector firms with regulatory approval services and market access across Europe and the MENA regions. Its asset base is almost entirely intangible, with intellectual property comprising approximately $499.4 million of total assets.

Revenue drivers

• Affiliate Revenue Agreement (ARA) — Fixed monthly contributions of $17,000 from affiliated entities, or $204,000 annualized, is the stated driver of the increase in fiscal 2025 revenue to $204,000 from $110,911 in 2024. The company describes this as a related-party, non-arm's length transaction entered into during its pre-commercialization phase.
• Diagnostic services and licensing — The 10-Q attributes a roughly 11% decline in nine-month 2025 revenue to $94,200 (from $106,381) to reduced diagnostic service activity and lower one-time licensing income. No product-level revenue breakdown was provided.
• Regulatory approval and market access services — The company says it provides international medical-sector firms with regulatory approval services and market access for Europe and the MENA regions, but no revenue figures for this activity are disclosed in the excerpts.

Recent performance

Fiscal 2025 revenue was $204,000 versus $110,911 in 2024, and net income was $71,219 versus $761, with the company attributing the improvement primarily to related-party ARA revenue. Operating expenses rose to $132,781 in 2025 from $110,150. For the nine months ended September 30, 2025, revenue was $94,200, down about 11% from $106,381, while net income was $32,081 versus $13,448 as operating expenses fell to $62,119 from $92,933. At September 30, 2025, the balance sheet showed $499.4 million of total assets, consisting primarily of intangible assets, against $1,609 of liabilities and $13 of cash. The 10-K reports year-end 2025 cash of $6,813 against net cash used in operating activities of $6,312, despite reported net income.

Strategy

The company states it is transitioning from a development stage to an operational phase, emphasizing cost management, operational efficiency, and expansion of its intellectual property portfolio. Its stated strategy centers on development, commercialization, and distribution of medical solutions, including CS Protect-Hydrogel and MEDUSA-SDP, supported by partnerships and distribution agreements. It says it is shifting resources from product development to commercialization and expects operating expenses to rise as regulatory and commercialization activities continue, though timing and magnitude are uncertain. Growth is described as dependent on regulatory approvals, market acceptance, and managing financial resources. External liquidity is stated to come from related-party funding, potential equity financings, and strategic partnerships.

Risks

• Going concern — The 10-Q states these conditions raise substantial doubt about the company's ability to continue as a going concern, dependent on achieving profitability and obtaining additional financing.
• Revenue concentration in related party — The ARA is a non-arm's length related-party arrangement that the company says does not reflect third-party customer revenue or core operations and may be terminated by any party on 30 days' notice.
• Minimal cash and negative operating cash flow — Cash was $6,813 at December 31, 2025 and $13 at September 30, 2025, with $6,312 of net cash used in operating activities in 2025 and no established recurring source of operating cash flow.
• Intangible-heavy asset base — Approximately $499.4 million of total assets consists primarily of acquired intellectual property that is non-cash in nature, and recoverability depends on achieving future commercialization or otherwise realizing value.
• Restated financials — An 8-K dated June 23, 2026 indicates previously issued financials are not reliable.

Outlook

Management says it expects ongoing operational revenues and capital infusions to support continuing operations through 2026, and states that capital requirements will continue to be met through shareholder support and, if necessary, external financing. It anticipates new service agreements and expanded diagnostic offerings may stabilize and potentially increase revenues during the remainder of 2025, and expects operating expenses to increase with commercialization and regulatory activities, though timing and magnitude remain uncertain.